Department of Pharmacology, Faculty of Pharmacy, Zagazig University, Zagazig, 44519, Egypt.
Faculty of Pharmacy, Zagazig University, Zagazig, 44519, Egypt.
Naunyn Schmiedebergs Arch Pharmacol. 2022 Nov;395(11):1357-1372. doi: 10.1007/s00210-022-02279-3. Epub 2022 Aug 10.
Dipeptidyl peptidase 4 (DPP4) inhibitors are a class of antidiabetic medications that cause glucose-dependent increase in incretins in diabetic patients. One of the two incretins, glucagon-like peptide-1 (GLP-1), beside its insulinotropic activity, has been studied for extra pancreatic effects. Most of DPP4 inhibitors (DPP4i) have been investigated in in vivo and in vitro models of diabetic and nondiabetic cardiovascular diseases including heart failure, hypertension, myocardial ischemia or infarction, atherosclerosis, and stroke. Results of preclinical studies proved prominent therapeutic potential of DPP4i in cardiovascular diseases, regardless the presence of diabetes. This review aims to present an updated summary of the cardiovascular protective and therapeutic effects of DPP4 inhibitors through the past 5 years focusing on the molecular mechanisms beneath these effects. Additionally, based on the results summary presented here, future studies may be conducted to elucidate or illustrate some of these findings which can add clinical benefits towards management of diabetic cardiovascular complications.
二肽基肽酶 4（DPP4）抑制剂是一类抗糖尿病药物，可使糖尿病患者的肠降血糖素依赖葡萄糖增加。两种肠降血糖素之一，胰高血糖素样肽-1（GLP-1），除了其胰岛素促分泌作用外，还研究了其胰腺外作用。大多数 DPP4 抑制剂（DPP4i）已在糖尿病和非糖尿病心血管疾病的体内和体外模型中进行了研究，包括心力衰竭、高血压、心肌缺血或梗死、动脉粥样硬化和中风。临床前研究结果证明，DPP4i 在心血管疾病中有显著的治疗潜力，无论是否存在糖尿病。本综述旨在通过过去 5 年的研究，总结 DPP4 抑制剂在心血管保护和治疗方面的最新进展，重点介绍这些作用背后的分子机制。此外，根据这里呈现的结果总结，未来的研究可以进一步阐明或说明其中一些发现，这可能会为糖尿病心血管并发症的管理带来临床益处。
